Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Not Recruiting

Trial ID: NCT01227954


RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain metastases.

Official Title

A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases

Stanford Investigator(s)

Scott G. Soltys, MD
Scott G. Soltys, MD

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery

Quynh-Thu Le, MD
Quynh-Thu Le, MD

Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

Iris C. Gibbs, MD, FACR, FASTRO
Iris C. Gibbs, MD, FACR, FASTRO

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery



   - Histologically or cytologically confirmed non-hematopoietic malignancy within the past
   5 years

      - If histologic proof of malignancy is from > 5 years ago, then a more recent
      pathological confirmation is required (e.g., from systemic metastatic or brain

      - Patients with metastasis of unknown primary tumor are permitted

   - Measurable brain metastasis outside a 5-mm margin around either hippocampus on
   gadolinium contrast-enhanced MRI obtained within the past 30 days

   - Have not been or will not be treated with stereotactic radiosurgery (SRS) or surgical

      - These treatment options are allowed only at relapse

   - Patients who have brain metastases at initial presentation allowed and do not need to
   demonstrate 3 months of stable scans

   - At least 1 week since open biopsy

   - Karnofsky performance status 70-100%

   - Fertile patients must use effective contraception

   - Negative pregnancy test 2 weeks or less prior to study entry

   - Patients must be English proficient, with patients who speak English as a second
   language eligible


   - Small cell lung cancer or germ cell malignancy

   - Leptomeningeal metastases

   - Non-small cell lung cancer-associated brain metastases with ≥ 2 organ sites of
   extracranial metastases

   - Radiologic evidence of hydrocephalus

   - Serum creatinine > 1.4 mg/dL within 30 days prior to study entry

   - Pregnant or nursing

   - Contraindication to MRI imaging such as implanted metal devices or foreign bodies or
   severe claustrophobia

   - Severe, active co-morbidity including any of the following:

      - Unstable angina and/or congestive heart failure requiring hospitalization within
      the past 6 months

      - Transmural myocardial infarction within the past 6 months

      - Acute bacterial or fungal infection requiring intravenous antibiotics

      - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

      - Chronic obstructive pulmonary disease exacerbation or other respiratory illness
      requiring hospitalization or precluding study therapy

      - Uncontrolled, clinically significant cardiac arrhythmias

   - Prior radiotherapy to the brain

   - Plan for chemotherapy or targeted therapies during WBRT or during the subsequent 7


radiation: intensity-modulated radiation therapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jacob Wynne

New Trial Alerts

Receive email alerts when trials open to patients.